Aclaris Announces Fully Funded Clarity Trial for Nociscan
Aclarion, Inc. (Nasdaq: ACON, ACONW) has secured approximately $20 million to fully fund its pivotal CLARITY trial. This trial...
Aclarion, Inc. (Nasdaq: ACON, ACONW) has secured approximately $20 million to fully fund its pivotal CLARITY trial. This trial...
The report “Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028” explores the burgeoning field of...
Nexalin Technology, Inc. announced positive results from a clinical study published in the Journal of Affective Disorders, showing its...
Tenaya Therapeutics received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund its Phase...
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial at MD...
GH Research PLC announced positive Phase 2b trial results for GH001, an inhalable mebufotenin treatment for treatment-resistant depression (TRD)....
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed to offer superior, long-lasting protection...
Median Technologies announced positive top-line results from its RELIVE study for eyonis™ LCS, an AI-powered lung cancer screening software....
Researchers found that C2N Diagnostics‘ PrecivityAD2 blood test improved healthcare providers’ ability to assess the likelihood of Alzheimer’s diseaseAlzheimer’s...
Eli Lilly’s Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn’sCrohn’s disease. Despite...